Vera Therapeutics (VERA) News Today $23.59 +1.57 (+7.13%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$23.05 -0.54 (-2.29%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgANApril 3 at 8:00 AM | globenewswire.comPrudential Financial Inc. Grows Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Prudential Financial Inc. grew its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 33.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 83,077 shares of the company's stock after aApril 3 at 3:51 AM | marketbeat.comVera Therapeutics (NASDAQ:VERA) Reaches New 52-Week Low - Here's WhyVera Therapeutics (NASDAQ:VERA) Sets New 52-Week Low - What's Next?April 2 at 4:11 AM | marketbeat.comAmerican Century Companies Inc. Has $18.14 Million Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)American Century Companies Inc. grew its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 11.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 428,940 shares of theApril 2 at 3:41 AM | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Gap Down - Should You Sell?Vera Therapeutics (NASDAQ:VERA) Shares Gap Down - Here's WhyApril 1 at 1:17 PM | marketbeat.comPictet Asset Management Holding SA Boosts Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)Pictet Asset Management Holding SA increased its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 47.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 841,313 shares of the company's stock aftApril 1 at 4:32 AM | marketbeat.com69,724 Shares in Vera Therapeutics, Inc. (NASDAQ:VERA) Bought by Raymond James Financial Inc.Raymond James Financial Inc. bought a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 69,724 shares of the company's stock, valued at approximately $2March 30, 2025 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Hits New 1-Year Low - Should You Sell?Vera Therapeutics (NASDAQ:VERA) Hits New 1-Year Low - What's Next?March 27, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), Erasca (ERAS)March 27, 2025 | markets.businessinsider.comEFG Asset Management North America Corp. Acquires 27,192 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)EFG Asset Management North America Corp. boosted its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 59.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 73,160 shares of the company's stock after purMarch 26, 2025 | marketbeat.comSwiss National Bank Purchases 15,700 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Swiss National Bank grew its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 22.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 85,400 shares of the company's stock after purchasing anMarch 26, 2025 | marketbeat.comPlatinum Investment Management Ltd. Has $5.06 Million Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Platinum Investment Management Ltd. decreased its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 12.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 119,664 shares of the comMarch 20, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. raised its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 19.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 430,665 shares of the company's stock after buying an additional 68,860 shares durinMarch 20, 2025 | marketbeat.comVictory Capital Management Inc. Increases Stake in Vera Therapeutics, Inc. (NASDAQ:VERA)Victory Capital Management Inc. grew its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 515.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 235,267 shares of the company's stock after aMarch 14, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of "Buy" by AnalystsShares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have been assigned a consensus rating of "Buy" from the ten analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation, six have given a buy recommendation and threMarch 12, 2025 | marketbeat.comVera Therapeutics (VERA) Expected to Announce Quarterly Earnings on WednesdayVera Therapeutics (NASDAQ:VERA) will be releasing earnings before the market opens on Wednesday, March 19, Financial Modeling Prep reports.March 12, 2025 | marketbeat.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 11, 2025 | globenewswire.comFY2025 Earnings Forecast for VERA Issued By HC WainwrightVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - HC Wainwright issued their FY2025 EPS estimates for Vera Therapeutics in a report released on Wednesday, March 5th. HC Wainwright analyst E. Arce forecasts that the company will earn ($2.40) per share for the year. The consensus estimate for VMarch 8, 2025 | marketbeat.comVera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much?March 7, 2025 | seekingalpha.comCantor Fitzgerald Has Negative View of VERA FY2025 EarningsVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of Vera Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that thMarch 7, 2025 | marketbeat.comCandriam S.C.A. Sells 84,993 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Candriam S.C.A. decreased its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 18.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 365,999 shares of the company's stock afteMarch 7, 2025 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Given New $71.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. reduced their price objective on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research note on Tuesday.March 5, 2025 | marketbeat.comVera Therapeutics price target lowered to $71 from $77 at JPMorganMarch 4, 2025 | markets.businessinsider.comProtagonist Therapeutics price target raised to $57 from $53 at JPMorganMarch 4, 2025 | markets.businessinsider.comQ1 EPS Estimates for Vera Therapeutics Boosted by WedbushVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities research analysts at Wedbush raised their Q1 2025 EPS estimates for shares of Vera Therapeutics in a research note issued to investors on Thursday, February 27th. Wedbush analyst L. Chico now expects that the company will post earningMarch 3, 2025 | marketbeat.comFY2029 Earnings Forecast for VERA Issued By WedbushVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities researchers at Wedbush issued their FY2029 EPS estimates for shares of Vera Therapeutics in a note issued to investors on Thursday, February 27th. Wedbush analyst L. Chico forecasts that the company will earn $2.16 per share for the yMarch 1, 2025 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Trading Up 7.6% Following Strong EarningsVera Therapeutics (NASDAQ:VERA) Trading 7.6% Higher After Better-Than-Expected EarningsFebruary 28, 2025 | marketbeat.comGuggenheim Issues Positive Forecast for Vera Therapeutics (NASDAQ:VERA) Stock PriceGuggenheim raised their target price on Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a report on Thursday.February 28, 2025 | marketbeat.comVera Therapeutics price target raised to $61 from $59 at GuggenheimFebruary 27, 2025 | markets.businessinsider.comVera Therapeutics to Participate in the TD Cowen 45th Annual Health Care ConferenceFebruary 27, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Agilent (A) and Vera Therapeutics (VERA)February 27, 2025 | markets.businessinsider.comDelveInsight Business Research, LLP: The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsightFebruary 26, 2025 | finanznachrichten.deThe Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsightFebruary 26, 2025 | finance.yahoo.comVera Therapeutics (NASDAQ:VERA) Announces Earnings ResultsVera Therapeutics (NASDAQ:VERA - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11.February 26, 2025 | marketbeat.comVera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 26, 2025 | globenewswire.comVera Therapeutics selloff a buying opportunity, says Evercore ISIFebruary 18, 2025 | markets.businessinsider.comVera Therapeutics pullback a buying opportunity, says Cantor FitzgeraldFebruary 18, 2025 | markets.businessinsider.comTD Cowen Remains a Buy on Vera Therapeutics (VERA)February 17, 2025 | markets.businessinsider.comVera Therapeutics (NASDAQ:VERA) Hits New 1-Year Low - What's Next?Vera Therapeutics (NASDAQ:VERA) Hits New 12-Month Low - Here's WhyFebruary 15, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Buy" from BrokeragesVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has earned a consensus recommendation of "Buy" from the ten research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation andFebruary 15, 2025 | marketbeat.comVera Therapeutics stock hits 52-week low at $31.64February 14, 2025 | msn.comWolfe Research Upgrades Vera Therapeutics (NASDAQ:VERA) to "Strong-Buy"Wolfe Research raised shares of Vera Therapeutics to a "strong-buy" rating in a research report on Monday.February 5, 2025 | marketbeat.comJennison Associates LLC Has $34.42 Million Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Jennison Associates LLC increased its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 82.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 813,861 shares of the company's stock after buying an adFebruary 5, 2025 | marketbeat.comVera Therapeutics initiated with an Outperform at Wolfe ResearchFebruary 4, 2025 | markets.businessinsider.comWolfe Research Initiates Coverage of Vera Therapeutics (VERA) with Outperform RecommendationFebruary 4, 2025 | msn.comWolfe Research Initiates Coverage on Vera Therapeutics (NASDAQ:VERA)Wolfe Research started coverage on Vera Therapeutics in a research note on Tuesday. They set an "outperform" rating and a $49.00 price target for the company.February 4, 2025 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Trading Up 4.9% - Still a Buy?Vera Therapeutics (NASDAQ:VERA) Stock Price Up 4.9% - Here's What HappenedJanuary 29, 2025 | marketbeat.comSG Americas Securities LLC Increases Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)SG Americas Securities LLC lifted its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 116.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,270 shares of the company's stock after purchasing an adJanuary 29, 2025 | marketbeat.comVera started at buy by Goldman Sachs, atacicept potential citedJanuary 28, 2025 | msn.comVera Therapeutics (NASDAQ:VERA) Shares Gap Up - Here's What HappenedVera Therapeutics (NASDAQ:VERA) Shares Gap Up - Time to Buy?January 28, 2025 | marketbeat.com Remove Ads Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address VERA Media Mentions By Week VERA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERA News Sentiment▼0.990.56▲Average Medical News Sentiment VERA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERA Articles This Week▼74▲VERA Articles Average Week Remove Ads Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Axsome Therapeutics News Today Blueprint Medicines News Today Telix Pharmaceuticals Limited American Depositary Shares News Today Krystal Biotech News Today Elanco Animal Health News Today Verona Pharma News Today Nuvalent News Today Grifols News Today Vaxcyte News Today Cytokinetics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERA) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
